Cerevance announced Phase 3 success for solengepras in Parkinson’s disease, reporting reduced daily “off” time alongside improvements across other symptoms. The privately held company said it will now engage regulators about a potential approval path, positioning the therapy as an add-on option that does not act directly on dopamine. The result is notable in a category where many therapies target dopaminergic pathways, while solengepras is framed around a different biological mechanism intended to preserve motor control and reduce certain side effects tied to dopamine-based regimens. For the field, the key near-term question is whether the Phase 3 benefit and tolerability profile support regulatory review and how payers will evaluate “off time” reductions against existing options.